866-997-4948(US-Canada Toll Free)

Optic Neuropathy - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : Mar 2017

Category :

Pharmaceutical

No. of Pages : 48 Pages

Optic Neuropathy - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Optic Neuropathy Pipeline Review, H1 2017, provides an overview of the Optic Neuropathy (Ophthalmology) pipeline landscape.

Optic neuropathy is an inherited form of vision loss. Symptoms include eye pain or discomfort, numbness, tingling and clouding of vision. Predisposing factors include age, tobacco smoke, alcohol, cancer treating drugs, stress related chemicals, some antibiotics and cyanogens.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Optic Neuropathy Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Optic Neuropathy (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Optic Neuropathy (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Optic Neuropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 1 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.

Optic Neuropathy (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Optic Neuropathy (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Optic Neuropathy (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Optic Neuropathy (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Optic Neuropathy (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Optic Neuropathy (Ophthalmology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Optic Neuropathy (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Optic Neuropathy (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Optic Neuropathy Overview
Optic Neuropathy Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Optic Neuropathy Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Optic Neuropathy Companies Involved in Therapeutics Development
Amgen Inc
BioAxone BioSciences Inc
Inotek Pharmaceuticals Corp
Ironwood Pharmaceuticals Inc
PharmatrophiX Inc
Quark Pharmaceuticals Inc
Regenera Pharma Ltd
Optic Neuropathy Drug Profiles
BA-240 Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IWP-953 Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LM-22A4 Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit Sema3A for Glaucoma and Optic Neuropathy Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NT-501 Drug Profile
Product Description
Mechanism Of Action
R&D Progress
QPI-1007 Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RPh-201 Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Sema3A for Glaucoma and Optic Neuropathy Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for CNS Disorders and Ophthalmology Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Neurological and Ophthalmological Diseases Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Inhibit Connexin 43 for Optic Neuropathy Drug Profile
Product Description
Mechanism Of Action
R&D Progress
trabodenoson Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Optic Neuropathy Dormant Projects
Optic Neuropathy Product Development Milestones
Featured News & Press Releases
Apr 26, 2016: Inotek Pharmaceuticals Announces Poster Presentations on Trabodenoson at the ARVO 2016 Annual Meeting
Feb 28, 2014: Regenera Pharma has been initiated the Phase IIa study in patients with chronic Ischemic Optic Neuropathy
Sep 18, 2012: Neurotech Pharmaceuticals Provides Update On NT-501
Apr 30, 2011: Regenera Pharma received the final report of its safety study in minipigs and is moving to human studies
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Optic Neuropathy, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Optic Neuropathy Pipeline by Amgen Inc, H1 2017
Optic Neuropathy Pipeline by BioAxone BioSciences Inc, H1 2017
Optic Neuropathy Pipeline by Inotek Pharmaceuticals Corp, H1 2017
Optic Neuropathy Pipeline by Ironwood Pharmaceuticals Inc, H1 2017
Optic Neuropathy Pipeline by PharmatrophiX Inc, H1 2017
Optic Neuropathy Pipeline by Quark Pharmaceuticals Inc, H1 2017
Optic Neuropathy Pipeline by Regenera Pharma Ltd, H1 2017
Optic Neuropathy Dormant Projects, H1 2017

List of Figures
Number of Products under Development for Optic Neuropathy, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Targets, H1 2017
Number of Products by Stage and Targets, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *